Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classifica tra le azioni #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Prezzo delle azioni
$8.74
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$699.74M
Variazione (1 giorno)
-4.85%
Variazione (1 anno)
-2.29%
Paese
US
Scambia BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

Storico del prezzo dell'azione per BridgeBio Oncology Therapeutics Inc. (BBOT)
Prezzo di chiusura più alto: $9.16 il 2026-08-01

Prezzo di chiusura più basso: $10.40 il 2024-02-01
Storico del prezzo dell'azione di BridgeBio Oncology Therapeutics Inc. dal 2024 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -16.90%
2025 15.50%
2024 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH